Despite their high collective burden, the rarity of individual paediatric cancers has translated into very limited market-driven innovation with slow pace innovation. Since 2007 only 9 medicines were introduced solely for paediatric cancer indication, compared to over 150 medicines for adult cancers.
Goals of the subpillar:
– Budget allocations to novel developments in paediatric cancer research to enable stable and sustainable international research platforms for paediatric cancer to enrich research through big data and use of AI.
– Improve access to compounds for preclinical testing and biological studies that would identify new targeted treatment strategies.
– Consideration to leverage the research potential of European Reference Networks.
– Involvement of patient advocates in novel and safer treatments with less side-effects and long-term sequelae, tailored to patient-centred approach.